Search

To investigate the prevalence of ESBL-producing Enterobacteriaceae from blood specimens sent to Microbiology Laboratory RSUP H. Adam Malik and its antibiotic susceptibility pattern to various antibiotics We conducted a retrospective study on blood specimens sent to Microbiology Laboratory RSUP H. Adam Malik, January 2019 - March 2021. The Vitek-2 compact system (bioMerieux®) performed identification and susceptibility testing with Advanced Expert System (AES). In addition, ESBL phenotypic screening was performed with the VITEK 2 compact, which compared the proportion of decreased bacterial growth to cefepime, cefotaxime, and ceftazidime, alone and in the presence of clavulanic acid. We found 1040 isolates from positive blood culture. A total of 333 (32,0%) isolates of Enterobactericeae were identified. From those isolates, there are 60,7% isolates were ESBL-producing Enterobactericeae , consisted of 121 (59,9%) Klebsiella pneumoniae , 76 (37,6%) Escherichia coli , 3(1,5%) isolat Klebsiella oxytoca and 2 (1%). ESBL-producing K.pneumoniae were susceptible to ertapenem (99,2%), meropenem (97,5%), amikacin (95,9%), tigecycline (90,9%), piperacillin-tazobactam (78,5%), cephalosporin (0-60,3%), trimethoprim-sulfamethoxazole (31,4%), ciprofloxacin (25,6%), gentamicin (20,7%), ampicillin sulbactam (19%), aztreonam (4,1%), amoxicillin (0%). ESBL - producing E coli were susceptible to meropenem, ertapenem, amikacin (100%), tigecycline (98,7%), piperacillin-tazobactam (88,2%), gentamicin (53,9%), cephalosporin (0% - 55,3%), ampicillin sulbactam (38,2%), trimethoprim-sulfamethoxazole (22,4%), ciprofloxacin (14,5%), aztreonam (11,8%),amoxicillin(0%). The prevalence of ESBL-producing Enterobacteriaceae from blood specimens, is high and most isolates highly sensitive toward tigecycline, amikacin, meropenem and ertapenem. [ABSTRACT FROM AUTHOR]